Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Novocure Inc. is a global oncology company dedicated to extending survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer cell division. Novocure's primary product, Optune Gio® (formerly Optune®), is a non-invasive, portable medical device approved for the treatment of adult patients with glioblastoma (GBM) and in combination with chemotherapy for malignant pleural mesothelioma (MPM). The company is actively conducting clinical trials to evaluate the safety and efficacy of TTFields in various other solid tumor types, including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and brain metastases.
The Root, Switzerland office serves as Novocure's global headquarters, overseeing international operations, strategic planning, and corporate functions. It supports European commercial activities and global coordination.
Modern office facilities designed to support a multinational biotechnology company, likely emphasizing collaborative workspaces and advanced communication technology.
The work culture at Novocure's headquarters likely reflects a blend of Swiss precision and global ambition, focusing on innovation, scientific rigor, and a patient-centric approach to oncology.
The Swiss headquarters provides a central hub for Novocure's expanding European and global operations, access to a skilled international workforce, and a stable regulatory environment.
Novocure operates globally with key functions distributed across North America, Europe, and Asia. This includes commercial operations in the U.S., Germany, Austria, Switzerland, Sweden, Japan, and Greater China; research and development primarily in Haifa, Israel, and supported by U.S. sites; global clinical trial management; and corporate functions headquartered in Switzerland. Their therapies are available in multiple countries, supported by regional offices and local teams focused on patient care, physician education, and market access.
Park 6
Root D4
Lucerne
Switzerland
Address: 195 Commerce Way, Portsmouth, NH 03801, USA
Manages and expands Novocure's presence in the North American oncology market, ensuring patient access to TTFields therapy.
Address: 20 Valley Stream Parkway, Malvern, PA 19355, USA
Supports U.S.-based and global clinical development efforts, crucial for expanding TTFields indications.
Address: Building 30, MATAM Advanced Technology Park, Haifa, 3190500, Israel
Drives the core scientific and technological advancements for Novocure's TTFields therapy platform.
Address: Marunouchi Kitaguchi Building 9F, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan
Facilitates access to TTFields therapy for patients in Japan and expands Novocure's footprint in the Asian market.
Address: No. 22 Grenville Street, St. Helier, Jersey JE4 8PX, Channel Islands
Fulfills legal and corporate domicile requirements.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Novocure' leadership includes:
Novocure has been backed by several prominent investors over the years, including:
Novocure has experienced some key executive transitions over the past year, notably strengthening its commercial leadership.
Discover the tools Novocure uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Novocure Inc. primarily uses the email format combining the first initial and last name of an employee, followed by '@novocure.com'. Variations might exist, but this is the most common pattern observed.
[firstinitial][lastname]@novocure.com
Format
jdoe@novocure.com
Example
85%
Success rate
Novocure Investor Relations • May 2, 2024
Novocure announced its financial results for the first quarter of 2024, reporting net revenues of $138.6 million and providing updates on its clinical trial programs, including progress in the LUNAR, PANOVA-3, and METIS studies....more
Novocure Investor Relations • April 8, 2024
Novocure announced it would present nine scientific abstracts highlighting research on Tumor Treating Fields (TTFields) therapy at the AACR Annual Meeting 2024, showcasing ongoing efforts to understand TTFields' mechanisms of action and explore new applications....more
GlobeNewswire • March 19, 2024
Novocure and Lapix Therapeutics, Inc. entered into an exclusive license agreement for Lapix to develop and commercialize radiopharmaceutical products that utilize Novocure’s proprietary technology for targeted delivery to tumors. This marks Novocure's expansion into a new therapeutic modality....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Novocure, are just a search away.